Virtu Financial’s Sage Therapeutics SAGE Stock Holding History

Virtu Financial’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-56,515	Closed	-$515K	–	2005
2025 Q2	$515K	Buy	+56,515	New	+$416K	0.03%	565
2024 Q2	–	Sell	-10,003	Closed	-$187K	–	1810
2024 Q1	$187K	Buy	+10,003	New	+$231K	0.01%	809
2023 Q3	–	Sell	-17,793	Closed	-$837K	–	1819
2023 Q2	$837K	Buy	+17,793	New	+$885K	0.06%	257
2019 Q4	$732K	Buy	10,137 +8,227	+431%	+$1.01M	0.07%	302
2019 Q3	$268K	Buy	+1,910	New	+$320K	0.02%	813
2018 Q4	–	Sell	-4,895	Closed	-$691K	–	1927
2018 Q3	$691K	Buy	+4,895	New	+$756K	0.04%	463
2018 Q2	–	Sell	-3,611	Closed	-$582K	–	2432
2018 Q1	$582K	Buy	+3,611	New	+$613K	0.03%	627

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Virtu Financial's SAGE Position: Q3 2025 in Review

Virtu Financial sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 56,515 shares — an estimated $515K sold.

Virtu Financial first reported a position in SAGE in Q1 2018 and held it in 7 quarters. The position peaked at $837K in Q2 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Virtu Financial reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Virtu Financial sold 56,515 Sage Therapeutics shares in Q3 2025, an estimated $515K.
Virtu Financial first reported a position in Sage Therapeutics in Q1 2018 and held it in 7 quarters.
Virtu Financial's Sage Therapeutics position peaked at $837K in Q2 2023.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.